Patient Preference clinical trials

Explore recruiting patient preference clinical trials.

Recruiting patient preference studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Patient Preference trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

TIming of start of systemIc treatment for asymptomatic MEtastasized PANcreatic cancer (TIMEPAN): a prospective multicenter patient preference cohort

Netherlands

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 2 Study to Evaluate Patient Reported Preference for Subcutaneous Pembrolizumab Coformulated with Hyaluronidase (MK-3475A) Over Intravenous Pembrolizumab Formulation in Participants With Multiple Tumor Types (MK-3475A-F11)

Poland, France

Therapeutic exploratory (Phase II) EU CTIS Study details

Rectal preserving treatment for early rectal cancer. A multi-centred, partially randomised, patient-preference trial of radical surgery versus adjuvant chemoradiotherapy after local excision for early rectal cancer.

Netherlands, France

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 2 Open-label, Two-cohort Study to Evaluate Patient Preference for nivolumab + relatlimab Fixed-dose Combination Subcutaneous versus nivolumab + relatlimab Fixed-dose Combination Intravenous and nivolumab Subcutaneous versus nivolumab Intravenous in Participants with Melanoma

Italy, Greece, Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase IIIB, Multinational, Multicenter, Randomized, Open-Label Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administrationin Participants with Early or Locally Advanced/ Inflammatory HER2-Positive Breast Cancer

Spain, Bulgaria, Croatia

Therapeutic confirmatory (Phase III) EU CTIS Study details

Ravulizumab dose optimization

Netherlands

Therapeutic use (Phase IV) EU CTIS Study details

Patient Preference trials by city

Patient Preference in Toronto Patient Preference in Vancouver Patient Preference in Montreal Patient Preference in Calgary Patient Preference in Edmonton Patient Preference in Ottawa Patient Preference in Winnipeg Patient Preference in Quebec City Patient Preference in Hamilton Patient Preference in Kitchener Patient Preference in London Patient Preference in Halifax Patient Preference in New York Patient Preference in Los Angeles Patient Preference in Chicago Patient Preference in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease